Lung cancer immunotherapy: progress, pitfalls, and promises
A Lahiri, A Maji, PD Potdar, N Singh, P Parikh, B Bisht… - Molecular cancer, 2023 - Springer
Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Rational combinations of targeted cancer therapies: background, advances and challenges
Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …
First-line immunotherapy for non–small-cell lung cancer
For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …
been characterized by critical progress that has contributed to substantially improved …
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
AJ Korman, SC Garrett-Thomson… - Nature Reviews Drug …, 2022 - nature.com
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …
discussion and experimentation for over a hundred years. Several successful cancer …
Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON …
ML Johnson, BC Cho, A Luft… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus
durvalumab and chemotherapy (T+ D+ CT) and durvalumab plus chemotherapy (D+ CT) …
durvalumab and chemotherapy (T+ D+ CT) and durvalumab plus chemotherapy (D+ CT) …
Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial)
PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials. gov …
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials. gov …
Toward personalized treatment approaches for non-small-cell lung cancer
M Wang, RS Herbst, C Boshoff - Nature medicine, 2021 - nature.com
Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
M Gogishvili, T Melkadze, T Makharadze… - Nature medicine, 2022 - nature.com
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …